Treatment
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial
The Lancet. Respiratory Medicine 2026 April [Link] Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice Milne, Amelia Clive, Rahul Bhatnagar, Mark E Roberts, Thapas Nagarajan, Farheen Kutubudin, Helen Wassal, Moustafa Aboushehata, Sana Iftikhar, Mohammed Haris, Manjumol Abraham, Rajini Sudhir, Rakesh…
Read MoreTargeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Cell Death & Disease 2026 February 28 [Link] Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Yinzhi Lin, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Pleural mesothelioma (PM)…
Read MoreImmune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers
Current Oncology 2026 February 3 [Link] Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano Abstract Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum-pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous,…
Read MoreClinical Importance of Molecular Biomarkers in Pleural Mesothelioma
Cancers 2026 February 19 [Link] Logan Roof, Kenna Koehler, Claire Verschraegen Abstract Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances in systemic therapy. While histology remains the most clinically relevant prognostic indicator, the expanding use of immunotherapy and ongoing clinical trials involving targeted therapies have…
Read MoreFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon, Toby Talbot, Francesco Grossi, Dariusz Kowalski, Muhammet A Kaplan, Andrés Felipe Cardona, Raheela Soomro, Nan Hu, Adam Lee, Virginia Ip, Yu-Han Hung, Gérard Zalcman Abstract…
Read MoreMesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models
Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma de Jong, Joel Kidman, Rachael M Zemek, Catherine A Rinaldi 6, Timo Lassmann 3, Anthony Bosco 7, Y C Gary Lee, Richard A Lake, Jonathan…
Read MorePresent and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review
European Respiratory Review 2026 February 18 [Link] Amro Hajja, Miral Atout, Rasoul Turko, Haadi Syed, Paula Duarte D’Ambrosio, Ricardo Mingarini Terra, Amal Abdulhaq, Marco Nardini, Marcello Carlo Ambrogi, Marco Lucchi, Hassan Robaidi, Waleed Saleh, Khaled AlKattan, Marcello Migliore Abstract Background: Pleural malignancies pose a significant clinical challenge due to their poor prognosis and limited treatment…
Read MoreAnalysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study
Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant…
Read MoreOptimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies
Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been challenged since 2020 by dual immunotherapy, that is, anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors and recently by combination of…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read More
Skip to content